Finally, we also demonstrate that Nrf2 activation ameliorates AKI induced by intravascular hemolysis both in vivo and in cultured tubular epithelial cells, indicating that Nrf2 may be a therapeutic target for the treatment of these diseases. This evidence concerns the gene NFE2L2 and acute kidney injury.